TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 20.36%49.91B | 12.46%83.89B | 33.66%41.47B | -12.87%74.6B | -14.47%31.03B | 59.95%85.62B | 60.27%36.28B | 31.79%53.53B | 14.26%22.63B | 17.54%40.61B |
Operating income | 20.36%49.91B | 12.46%83.89B | 33.66%41.47B | -12.87%74.6B | -14.47%31.03B | 59.95%85.62B | 60.27%36.28B | 31.79%53.53B | 14.26%22.63B | 17.54%40.61B |
Cost of sales | -23.24%-47.37B | -14.25%-77.93B | -34.18%-38.44B | 15.79%-68.21B | 16.58%-28.65B | -68.62%-80.99B | -67.36%-34.34B | -33.70%-48.03B | -14.26%-20.52B | -17.92%-35.93B |
Operating expenses | -23.24%-47.37B | -14.25%-77.93B | -34.18%-38.44B | 15.79%-68.21B | 16.58%-28.65B | -68.62%-80.99B | -67.36%-34.34B | -33.70%-48.03B | -14.26%-20.52B | -17.92%-35.93B |
Gross profit | -16.08%2.55B | -6.65%5.96B | 27.49%3.03B | 38.27%6.39B | 23.01%2.38B | -15.86%4.62B | -8.57%1.93B | 17.16%5.49B | 14.23%2.12B | 14.74%4.69B |
Selling expenses | 4.53%-643.41M | -15.86%-1.42B | -46.00%-673.96M | -18.53%-1.23B | -12.77%-461.61M | -10.62%-1.04B | -8.32%-409.35M | -4.57%-937.66M | 9.05%-377.9M | -0.76%-896.68M |
Administrative expenses | 6.51%-650.67M | 0.43%-1.36B | -22.49%-695.97M | -37.75%-1.36B | -28.71%-568.19M | -25.05%-989.38M | -24.95%-441.46M | -19.33%-791.15M | -22.46%-353.3M | -17.62%-662.97M |
Research and development expenses | -13.60%-942.16M | -18.79%-1.93B | -16.98%-829.34M | -9.39%-1.62B | -15.13%-708.94M | -16.74%-1.48B | -15.62%-615.79M | -10.11%-1.27B | -5.17%-532.61M | -3.55%-1.15B |
Impairment and provision | 44.20%-35.85M | 61.25%-55.44M | -103.48%-64.25M | -26.09%-143.06M | -67.61%-31.58M | -1,113.72%-113.46M | 0.94%-18.84M | 71.28%-9.35M | -548.70%-19.02M | -41.46%-32.55M |
-Other impairment is provision | 44.20%-35.85M | 61.25%-55.44M | -103.48%-64.25M | -26.09%-143.06M | -67.61%-31.58M | -1,113.72%-113.46M | 0.94%-18.84M | 71.28%-9.35M | -548.70%-19.02M | -41.46%-32.55M |
Special items of operating profit | 83.38%1.38B | 76.03%1.85B | 14.03%750.41M | -4.29%1.05B | 4.87%658.11M | 61.37%1.1B | 63.03%627.57M | 54.49%679.19M | 66.29%384.95M | 54.41%439.63M |
Operating profit | 8.50%1.65B | -1.08%3.05B | 19.98%1.52B | 47.13%3.08B | 17.72%1.27B | -33.80%2.09B | -11.61%1.08B | 32.81%3.16B | 38.78%1.22B | 33.82%2.38B |
Financing cost | -18.72%-282.16M | -41.69%-482.78M | -54.98%-237.68M | -34.10%-340.74M | -30.29%-153.36M | -19.78%-254.09M | -10.71%-117.71M | 16.82%-212.13M | 20.28%-106.32M | -43.49%-255.04M |
Share of profits of associates | -18.55%-620K | 7.73%-835K | -202.95%-523K | 66.91%-905K | 189.28%508K | -252.45%-2.74M | -68.84%-569K | -205.51%-776K | ---337K | -108.13%-254K |
Earning before tax | 6.60%1.37B | -6.40%2.56B | 15.06%1.28B | 49.10%2.74B | 16.30%1.11B | -37.73%1.84B | -13.76%958.27M | 38.74%2.95B | 49.32%1.11B | 32.47%2.13B |
Tax | -9.85%-301.31M | -10.41%-727.78M | -28.58%-274.29M | -130.69%-659.16M | 0.76%-213.32M | 35.81%-285.73M | 14.39%-214.95M | -11.26%-445.15M | -63.75%-251.09M | -31.56%-400.09M |
After-tax profit from continuing operations | 5.72%1.07B | -11.73%1.84B | 11.85%1.01B | 34.07%2.08B | 21.23%901.15M | -38.06%1.55B | -13.58%743.32M | 45.11%2.5B | 45.57%860.14M | 32.68%1.73B |
Earning after tax | 5.72%1.07B | -11.73%1.84B | 11.85%1.01B | 34.07%2.08B | 21.23%901.15M | -38.06%1.55B | -13.58%743.32M | 45.11%2.5B | 45.57%860.14M | 32.68%1.73B |
Minority profit | 53.05%137.39M | -95.10%13.87M | -36.51%89.77M | 12.75%283.29M | 71.47%141.39M | 808.58%251.26M | 252.66%82.46M | -37.33%27.65M | 567.08%23.38M | -8.77%44.12M |
Profit attributable to shareholders | 1.09%928.22M | 1.42%1.82B | 20.86%918.21M | 38.19%1.8B | 14.96%759.75M | -47.52%1.3B | -21.02%660.86M | 47.28%2.48B | 40.42%836.76M | 34.29%1.68B |
Basic earnings per share | 1.09%0.8243 | 1.25%1.62 | 20.85%0.8154 | 39.13%1.6 | 14.98%0.6747 | -47.73%1.15 | -20.99%0.5868 | 47.65%2.2 | 40.42%0.7427 | 34.23%1.49 |
Diluted earnings per share | 1.73%0.8124 | 1.27%1.59 | 20.58%0.7986 | 38.94%1.57 | 15.71%0.6623 | -47.44%1.13 | -21.42%0.5724 | 46.26%2.15 | 40.51%0.7284 | 34.86%1.47 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Zhonghui Anda Certified Public Accountants Co., Ltd. | -- | Zhonghui Anda Certified Public Accountants Co., Ltd. | -- | Zhonghui Anda Certified Public Accountants Co., Ltd. |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.